Designing a Large Language Model Architecture for Shared Decision Making and Informed Intentions (DEONCAI3-1)
DEONCAi 3-1: Can Large Language Models Support Shared Decision-Making and Informed Intentions in the Field: An Online Experiment Comparing Them to a Standard Model and to an Evidence-Based Decision Aid
調査の概要
状態
詳細な説明
Background & Current State of Research Shared Decision-Making is widely recognized as the gold standard of patient-centered care. However, its successful implementation in clinical practice is frequently hindered by systemic time and budget constraints. Consequently, patients are increasingly turning to Large Language Models to independently access health information and navigate their medical options.
The Problem: Limitations of Standard LLMs Recent studies indicate that using standard LLMs can digitally reproduce existing health inequalities and participation gaps. These models struggle to adapt to different reading levels without a significant loss in quality. While highly developed prompting techniques can enhance clinical accuracy, the results remain highly variable depending on the specific model and technique used.
A central deficit becomes apparent in multi-turn interactions, which are essential for a natural SDM workflow. In these prolonged conversations, standard LLMs tend to exhibit "context rot," leading to a sharp decline in accuracy as the dialogue progresses. This issue is further exacerbated by model sycophancy (an uncritical tendency to agree with the user) and completion eagerness (a tendency to prematurely conclude the conversation). Because current LLMs often fail to meet evidence-based reporting standards and lack systematic validation of user comprehension, the burden of fact-checking remains entirely on the user. This dynamic significantly disadvantages vulnerable groups, particularly those with lower health literacy.
Project Objectives and Research Questions
This project proposes a technical and clinical solution to these challenges through the following core research questions:
Technical-Conceptual Framework: How can we develop a transparent and replicable workflow that formalizes the SDM process through an agentic state-machine, thereby eliminating structural deficits of LLMs (e.g., context rot and sycophancy) in prolonged interactions?
Clinical Evaluation (Primary Objective): Does this newly developed agentic LLM architecture achieve higher scores in participatory conversation management and demonstrate a significantly greater objective increase in informed decision-making among users during multi-turn interactions, compared to a standard baseline LLM?
Health Equity (Secondary Objective): To what extent can this agentic LLM architecture guarantee effective participatory conversation management for vulnerable patient groups with low health literacy?
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Felix G Rebitschek, PhD
- 電話番号:+493319772162
- メール:felix.rebitschek@fgw-brandenburg.de
研究連絡先のバックアップ
- 名前:Martin Lipsdorf
- メール:martin.lipsdorf@mhb-fontane.de
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Biological sex: Female.
- Age: 40 to 70 years old.
- Country of residence: United States (US) or United Kingdom (UK).
- Language: Native English speaker (English as first language).
- Registered and verified user on the academic research platform Prolific.
- Able to read, understand, and provide informed consent digitally.
Exclusion Criteria:
- Individuals who do not meet the automated pre-screening criteria on the Prolific platform.
- Inability to use or access a computer, smartphone, or internet browser required to complete the digital study.
Note: Quotas will be enforced during recruitment to ensure a 50/50 stratified split between participants with and without university entrance qualifications to guarantee variance in educational backgrounds. Once a quota is filled, further participants matching that educational profile will be excluded.
-
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:ヘルスサービス研究
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Shared Decision Making Chatbot
Participants will engage in a multi-turn, AI-assisted consultation about mammography screening.
They will interact with a newly developed agentic Large Language Model architecture that uses an integrated state-machine designed to actively guide the Shared Decision-Making process, adapt to the user's reading level, and prevent context loss.
|
An interactive AI chatbot built with an agentic state-machine architecture designed to systematically guide users through the Shared Decision-Making process regarding mammography screening, with built-in ethical guardrails to prevent hallucination and sycophancy.
|
|
アクティブコンパレータ:Standard Chatbot
Participants will engage in a conversation about mammography screening using a standard, usual care Large Language Model (Mistral Large).
This model represents the current consumer standard for AI health queries and lacks the specialized agentic state-machine and SDM workflow guidance.
|
An unmodified, standard generative Large Language Model chatbot acting as a baseline control, used by participants to discuss mammography screening.
|
|
アクティブコンパレータ:Information brochure
Participants will receive and read the standard informational patient brochure on mammography screening published by the German Institute for Quality and Efficiency in Health Care (IQWiG).
This represents the current standard of care for patient information.
|
The standard digital informational brochure on mammography screening provided by the german Institute for Quality and Efficiency in Health Care (IQWiG), used as a usual care baseline for patient education.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Patient-Reported Quality of Shared Decision-Making
時間枠:Day 1
|
Assessed using the 9-item Shared Decision Making Questionnaire (SDM-Q-9).
This validated instrument measures the patient's perceived involvement in the medical decision-making process.
The questionnaire consists of 9 items, each rated on a 6-point scale ranging from 0 ("completely disagree") to 5 ("completely agree").
The raw scores are summed and multiplied by 20/9 to yield a total score ranging from 0 to 100.
Higher scores indicate a higher perceived quality and greater patient involvement in shared decision-making.
|
Day 1
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Multidimensional Informed Decision-Making
時間枠:Day 1
|
Based on Marteau's conceptualization of informed decision-making.
An informed decision is achieved when a participant has sufficient objective knowledge about mammography screening and their behavioral intention (to screen or not to screen) is congruent with their personal attitudes toward the screening.
This is calculated as a composite measure integrating an objective knowledge test, an attitude assessment, and a screening intention question.
Higher objective knowledge scores and higher attitude-intention congruence indicate a better-informed decision.
|
Day 1
|
|
Subjective Decisional Conflict
時間枠:Day 1
|
Assessed using a standardized Decisional Conflict Scale.
This measures the participant's perceived uncertainty in choosing a screening option, their clarity of personal values, and their feeling of being supported in decision-making.
Scores are transformed to a 0 to 100 scale.
Lower scores indicate less decisional conflict and greater decision certainty.
|
Day 1
|
|
Medical Accuracy and Safety of Generated Information
時間枠:Day 1
|
A quantitative and qualitative assessment of the medical accuracy of the AI-generated texts.
This is operationalized by counting the frequency (number of occurrences) and categorizing the severity of deviations from established medical evidence (i.e., misinformation or "hallucinations").
These deviations are identified via an integrated ethics module and/or expert review.
Lower frequencies and lower severity ratings indicate higher medical accuracy.
|
Day 1
|
協力者と研究者
捜査官
- 主任研究者:Felix G Rebitschek, PhD、Harding Center for Risk Literacy
出版物と役立つリンク
一般刊行物
- Rebitschek FG, Carella A, Kohlrausch-Pazin S, Zitzmann M, Steckelberg A, Wilhelm C. Evaluating evidence-based health information from generative AI using a cross-sectional study with laypeople seeking screening information. NPJ Digit Med. 2025 Jun 9;8(1):343. doi: 10.1038/s41746-025-01752-6.
- Mendel T, Singh N, Mann DM, Wiesenfeld B, Nov O. Laypeople's Use of and Attitudes Toward Large Language Models and Search Engines for Health Queries: Survey Study. J Med Internet Res. 2025 Feb 13;27:e64290. doi: 10.2196/64290.
- Laban, P., Hayashi, H., Zhou, Y., & Neville, J. (2025). Llms get lost in multi-turn conversation. arXiv preprint arXiv:2505.06120.
- Krenn C, Loder C, Berger N, Jeitler K, Semlitsch T, Siebenhofer A, Wilfling D. Automated Approaches of Text Simplification of Patient Education Materials: Scoping Review. J Med Internet Res. 2026 May 7;28:e88365. doi: 10.2196/88365.
- Keij SM, Branda ME, Montori VM, Brito JP, Kunneman M, Pieterse AH. Patient Characteristics and the Extent to Which Clinicians Involve Patients in Decision Making: Secondary Analyses of Pooled Data. Med Decis Making. 2024 Apr;44(3):346-356. doi: 10.1177/0272989X241231721. Epub 2024 Mar 4.
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- DEONCAI3-1
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
IPD 共有時間枠
IPD 共有アクセス基準
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。